Table 1 Demographics, traditional CV risk factors, comorbidities and the use of medication at baseline, stratified by outcome
All (n = 135) | Patients with event (n = 26) | Patients without event (n = 109) | P value | |
|---|---|---|---|---|
Conventional CV risk markers | ||||
Age (yrs) | 58.5 ± 10.0 | 64.2 ± 8.6 | 57.2 ± 9.9 | 0.001 |
Females n (%) | 35 (26) | 29 (27) | 6 (23) | 0.81 |
Diabetes duration (yrs) | 6.5 ± 6.3 | 5.6 ± 4.8 | 6.6 ± 6.4 | 0.46 |
BMI (kg/m2) | 30.0 ± 5.4 | 29.7 ± 6.2 | 30.1 ± 5.2 | 0.75 |
Systolic BP (mmHg) | 142 ± 20 | 144 ± 21 | 142 ± 20 | 0.60 |
Diastolic BP (mmHg) | 83 ± 10 | 83 ± 13 | 83 ± 9 | 0.81 |
HbA1c (%/mmol/mol) | 7.6 ± 1.6/59.3 ± 17.0 | 7.5 ± 1.6/58.3 ± 17.0 | 7.6 ± 1.6/59.6 ± 17.1 | 0.74 |
FBG (mmol/L) | 9.5 ± 3.2 | 9.4 ± 3.2 | 9.6 ± 3.3 | 0.80 |
Total cholesterol (mmol/L) | 4.9 ± 1.0 | 4.8 ± 1.4 | 5.0 ± 1.0 | 0.47 |
LDL cholesterol (mmol/L) | 2.8 ± 0.9 | 2.7 ± 0.8 | 2.9 ± 0.9 | 0.23 |
HDL cholesterol (mmol/L) | 1.3 ± 0.4 | 1.2 ± 0.3 | 1.3 ± 0.4 | 0.29 |
Triglycerides (mmol/L) | 1.9 ± 1.8 | 2.2 ± 3.2 | 1.8 ± 1.2 | 0.56 |
Creatinine (μmol/L) | 78.5 ± 15.3 | 86.7 ± 21.1 | 76.5 ± 12.9 | 0.025 |
Albuminuria (μg/min) | 16.0 (9.0, 30.5) | 22.0 (9.8, 39.0) | 15.0 (9.0, 28.3) | 0.091 |
Microalbuminuria n (%) | 56 (42) | 14 (54) | 42 (39) | 0.17 |
LVEF (%) | 63 ± 8 | 59 ± 8 | 64 ± 8 | 0.029 |
Daily smoking n (%) | 16 (12) | 3 (12) | 13 (12) | 0.87 |
Known CAD at inclusion n (%) | 16 (12) | 8 (31) | 8 (7) | 0.002 |
Known CVD at inclusion n (%)* | 22 (16) | 10 (39) | 12 (11) | 0.001 |
Framingham 10 years risk of CHD (%) | 9.6 ± 6.6 | 12.7 ± 6.9 | 8.9 ± 6.4 | 0.022 |
Medications | ||||
Numbers of Blood glucose lowering medications | 1.2 ± 0.9 | 1.4 ± 0.9 | 1.2 ± 0.9 | 0.29 |
Numbers of BP-lowering medications† | 0.9 ± 1.0 | 1.1 ± 1.2 | 0.9 ± 1.0 | 0.39 |
On statins n (%) | 61 (45) | 14 (54) | 47 (50) | 0.38 |
On ASA n (%) | 45 (33) | 12 (46) | 33 (30) | 0.16 |